Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Conditions
Interventions
Viltolarsen
Locations
31
Australia
Queensland Children's Hospital
Brisbane, Australia
The Childrens Hospital at Westmead
Westmead, Australia
CHU de Quebec Research Centre
Québec, Canada
Hospital de Niños Roberto del Rio
Santiago, Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Chinese PLA General Hospital
Beijing, China
Start Date
April 13, 2021
Primary Completion Date
October 1, 2025
Completion Date
November 1, 2025
Last Updated
February 14, 2024
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
NS Pharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions